Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program
Abstract Background and Aim: Data on the clinical pharmacokinetics of cannabidiol (CBD) are scanty. We explored the effect of demographic…
Abstract Background and Aim: Data on the clinical pharmacokinetics of cannabidiol (CBD) are scanty. We explored the effect of demographic…
Abstract Simple Summary: Glioblastoma (GBM) is the most frequent primary brain tumor entity with poor prognosis and resistance to current…
Authors: Weimar Kunz Sebba Barroso ⚬, Cibele Isaac Saad Rodrigues ⚬, Luiz Aparecido Bortolotto ⚬, Marco Antônio Mota-Gomes ⚬, Andréa…
Abstract The objective of this work has been to characterize the estrogenic activity of bisphenol-A (BPA) and the adverse effects…
Abstract Fourier Transform Infrared (FT-IR) spectroscopy and imaging combined with hierarchical cluster analysis (HCA) was applied to analyse biochemical properties…
Abstract Background: Evidence suggests that an overlap exists between the neurobiology of psychotic disorders and the effects of cannabinoids on…
Abstract Movement disorders are the most common neurological category of qualifying conditions in the U.S. The number and action levels…
Abstract The medicinal properties of cannabis and the its legal status in several countries and jurisdictions has spurred the massive…
Abstract Cultivation of cannabis plants (Cannabis sativa L., marijuana) has taken place worldwide for centuries. In Canada, legalization of cannabis…
Abstract Cannabis/cannabinoids are widely used for recreational and therapy purposes, but their risks are largely disregarded. However, cannabinoid-associated use disorders…